TY - JOUR T1 - Diffusion lung capacity changes in Hodgkin lymphoma patients before and after ABVD chemotherapy JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2015.PA963 VL - 46 IS - suppl 59 SP - PA963 AU - Muhammad Abdullah AU - Shoaib Alam AU - Waleed Zafar AU - Abdul Majid AU - Ali Saeed Wahla Y1 - 2015/09/01 UR - http://erj.ersjournals.com/content/46/suppl_59/PA963.abstract N2 - Background: Bleomycin induced pulmonary toxicity is clinically detected using diffusing lung capacity for carbon monoxide (DLCO) in Hodgkin's Lymphoma (HL) patients after chemotherapy.Objective: To evaluate changes in DLCO in HL patients after ABVD chemotherapy.Methods: Medical records of all adult HL patients treated with ABVD chemotherapy at a single center in Lahore, Pakistan during the entire calendar year 2012 were analyzed. Patients with pre-existing pulmonary dysfunction, history of thoracic surgery and smokers were excluded.Results: Out of 179 patients, 93 (51.95%) patients had received both a pre- and post-chemotherapy DLCO. The mean percentage difference between pre- and post-chemotherapy values for DLCO (5.49%; 95% confidence interval [CI] 1.56%-9.43%) and for Hemoglobin-adjusted DLCO (8.24%; 95% CI 3.90%-12.57%) were statistically significant at p<0.01. After adjusting for age, a 1mg/m2 increase in dose of Bleomycin was significantly associated with 0.14% (95% CI: 0.03%-0.25%) decline in DLCO and 0.13% (95% CI: 0.10%-0.26%) decline in hemoglobin-adjusted DLCO from pretreatment value. p-valuePre and post DLCO0.007Pre and post Hemoglobin adjusted DLCO0.001Pre and post alveolar volume adjusted DLCO0.001Pre and post Hemoglobin and alveolar volume adjusted DLCO0.001Paired comparison of Diffusion Lung capacityConclusions: Mild to moderate dysfunction in diffusion lung capacity is common after ABVD chemotherapy. ER -